Farhad Rahaman
A5050520224- Immunotherapy and Immune Responses
- HIV Research and Treatment
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Blood groups and transfusion
- vaccines and immunoinformatics approaches
- Immunodeficiency and Autoimmune Disorders
International AIDS Vaccine Initiative
2022-2024
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial, the vaccine-priming candidate eOD-GT8 60mer adjuvanted with AS01
The engineered outer domain germline targeting version 8 (eOD-GT8) 60-mer nanoparticle was designed to prime VRC01-class HIV-specific B cells that would need be matured, through additional heterologous immunizations, into are able produce broadly neutralizing antibodies. CD4 T cell help will critical for the development of such high-affinity antibody responses. Thus, we assessed induction and epitope specificities vaccine-specific from IAVI G001 phase 1 clinical trial tested immunization...
Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise development of precision vaccines against major human pathogens. In a clinical trial the eOD-GT8 60mer germline-targeting immunogen, higher frequencies vaccine-induced VRC01-class bnAb-precursor B cells were observed in high dose compared to low group. Through immunoglobulin heavy chain variable (IGHV) genotyping, statistical modeling, quantification IGHV1-2 allele usage and...
Abstract Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise development of precision vaccines against major human pathogens. In a clinical trial the eOD-GT8 60mer germline-targeting immunogen, higher frequencies vaccine-induced VRC01-class bnAb-precursor B cells were observed in high dose compared to low group. Through immunoglobulin heavy chain variable (IGHV) genotyping, statistical modeling, quantification IGHV1-2 allele...